

Empowering The Visual Communication of Data Using Shiny R at KUCC

By Sam Pepper, MS

Senior Data Scientist

KUMC Department Biostatistics & Data Science

“You can have data without information,
but you cannot have information without
data”

-Daniel Keys Moran

Infrastructure Utilized

- Shinyapps.io (Free, Cloud)
- Shiny Server (Free, On-prem)
- Posit Connect (Paid, On-prem, Auth)

Shinyapps.io Applications

- Use Publicly Available Data
- Applications
 - <https://optik.shinyapps.io/OPTIK/>
 - https://optik.shinyapps.io/CIF_KUMC/
 - https://optik.shinyapps.io/CIF_Bivar_KUMC/
 - https://optik.shinyapps.io/CIF_Profiles_KUMC/

Single Year

Yearly

Year


2022

Update Variables

Choose One or More Variables (<4):

- Mental Health Provider Rate
- Poor or Fair Health
- Poor Physical Health Days
- Poor Mental Health Days
- Adult Smoking
- Excessive Drinking
- Dentist Rate
- Unemployment
- Children in Poverty
- Children in Poverty Black
- Children in Poverty Hispanic
- Children in Poverty White
- Drinking Water Violations
- Sexually Transmitted Infections

The Heat Map of Adult Smoking in 2022 in KUCC Catchment Area



*Research reported in this publication was supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 and used BISR core

Shiny Server/Posit Connect Applications

- Use Data from CTMS system (WCG Velos)
- Applications
 - Accrual
 - Study Startup
 - Data Safety Monitoring Board (DSMB)
 - Resourcing Efforts
 - Finance Reconciliation
 - Accrued Revenue

KUCC Accrual Summary

Research reported in this publication was supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 and used BISR core

Overall Summary

Patients

Patient Timeline

Studies

Studies Timeline

Data Breakdown

Date Range

2024-01-01

to

2024-04-12

Primary Research Category

Interventional

Primary Purpose

Treatment

Apply Filter

Total: 236

Data From: 2024-04-12

Research Category

Primary Purpose

Phase

Managed By

Therapeutic Area

Enrolling Site

Phase	Accrual	Accrual Percent
I	53	22.46%
I/II	33	13.98%
II	93	39.41%
II/III	6	2.54%
III	48	20.34%
N/A	3	1.27%

Gender

Race

Ethnicity

Age Group

RUCC Locality

HPSA

Participant Disease

Locality	Accrual	Accrual Percent
Missing	4	1.69%
Rural	43	18.22%
Urban	189	80.08%
Total	236	100%

Date Range

to

Primary Research Category

Primary Purpose

Study Source

Research Program

Phase

Managed By

Therapeutic Area

[Enrolling Site](#)[Gender](#)[Race](#)[Ethnicity](#)[Age Group](#)[RUCC Locality](#)[HPSA](#)[Participant Disease](#)

Race

Accrual

Accrual Percent

African American

72

65.45%

Missing

5

4.55%

Unknown

8

7.27%

White

25

22.73%

Total

110

100%

Date Range

to

Primary Research Category

Primary Purpose

Enrolling Site


Gender

Race


Ethnicity

Age At Enroll

Accrual By Month



Accrual By Year



Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total
2018	67	46	76	49	76	58	59	62	57	66	63	66	745
2019	63	44	86	82	87	97	93	95	93	103	83	78	1004
2020	79	95	81	52	46	77	87	123	90	101	70	79	980
2021	73	82	99	80	40	63	51	56	59	73	82	67	825
2022	56	50	60	66	70	83	65	89	82	102	97	87	907
2023	101	77	108	144	144	80	81	79	91	144	142	70	1261
2024	80	92	96	30									298

Date Range

to

Enrolling Site

Gender

Race

Ethnicity

Age At Enroll

RUCC Locality

HPSA

[Research Category](#)
[Primary Purpose](#)
[Study Source](#)
[Research Program](#)

Study Source

Accrual
Accrual Percent

Externally Peer-Reviewed/Federal Funding

91

12.48%

Industrial/Pharmaceutical

121

16.6%

Institutional/Investigator Initiated-KU or Partner

250

34.29%

Institutional/Investigator Initiated-Not KU or Partner

30

4.12%

National/Cooperative Group/Consortium

234

32.1%

Registry

3

0.41%

[Phase](#)
[Managed By](#)
[Therapeutic Area](#)
[Study Number](#)
Study Number
Accrual
Accrual Percent
Target Sample Size
Predicted Accrual Completion Date
Probability Late

30

4.12%

500

2031-11-02

100.00%

1

0.14%

350

2032-07-23

99.83%

3

0.41%

200

2027-11-14

100.00%

12

1.65%

139

2026-08-18

20.24%

41

5.62%

80

2024-04-12

Completed

11

1.51%



80

2025-10-02

99.99%

Accrual Prediction Plots

Here are the prediction plots:



Date Range

to

Primary Research Category

Primary Purpose

Study Source


Research Program

Phase


Managed By

Therapeutic Area

Accrual By Month



Accrual By Year



Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total
2018	49	39	54	31	44	37	42	36	37	42	37	49	497
2019	41	33	54	51	45	53	53	50	55	52	48	43	578
2020	37	57	55	36	36	45	48	62	46	55	41	42	560
2021	47	40	57	37	20	32	37	37	34	38	61	43	483
2022	42	41	49	42	52	46	33	52	35	43	50	54	539
2023	56	43	38	50	50	39	46	57	52	47	43	36	557
2024	40	60	62	23									185

Reset

Data From:
2024-04-12

Table ▾

Count as Fraction of Columns ▾ ↕ ↔

Enroll Year ▾

Enroll Month ▾

Enroll Year-Month ▾

Ethnicity ▾

Age At Enroll Group ▾

Age Group ▾

Study Number ▾

Managed By ▾

Study Sponsorid ▾

PI ▾

Program Alignment ▾

NCORP ▾

Patient Status ▾

Enrolling Site ▾

Patient Enrolled Status Date ▾

Gender ▾

Race ▾

		Enroll Year				
Gender	Race	2022	2023	2024	Totals	
Female	African American	5.7%	8.4%	10.8%	7.6%	
	American Indian or Alaska Native	0.2%	0.4%	0.4%	0.3%	
	Asian	0.8%	0.6%	0.1%	0.6%	
	Missing	0.3%	0.0%		0.1%	
	Native Hawaiian or other Pacific Islander	0.1%	0.0%		0.1%	
	Other	1.8%	1.5%	1.0%	1.5%	
	Unknown	1.9%	0.7%	0.7%	1.2%	
	White	47.7%	42.5%	37.9%	44.1%	
Male	African American	3.4%	7.8%	8.9%	6.1%	
	American Indian or Alaska Native	0.1%	0.2%		0.2%	
	Asian	0.5%	0.3%	0.4%	0.4%	
	Missing	0.1%	0.1%		0.1%	
	Native Hawaiian or other Pacific Islander	0.1%	0.1%		0.1%	
	Other	1.0%	1.0%	1.8%	1.1%	
	Unknown	1.8%	1.6%	1.8%	1.7%	
	White	34.6%	34.7%	36.0%	34.8%	
Totals		100.0%	100.0%	100.0%	100.0%	

Oldest Date Range

2023-01-01 to 2024-03-17

Primary Disease Working Group

No Filter

Principal Investigator (PI)

No Filter

Study Sponsor

No Filter

Stage

No Filter

Research Type

No Filter

Apply Filter

Data From: 2024-03-17

506

Total Studies:

90

PipeLine

257

PipeLine Withdrawn

12

DWG Submitted

1

DWG Not Approved

29

ERC Pending Submission

0

ERC Submitted

5

ERC Pending

3

ERC Not Approved

1

PRMC Pending Submission

6

PRMC Submitted

1

PRMC Tabled

0

PRMC Withdrawn

1

PRMC Not Approved

39

Activation Pending

61

Activated

Oldest Date Range

2023-01-01 to 2024-03-17

Primary Disease Working Group

No Filter

Principal Investigator (PI)

No Filter

Study Sponsor

No Filter

Stage

No Filter

Research Type

No Filter

Apply Filter

Data From: 2024-03-17

CSV Excel

Search:

Issuance Date Target	HSC Resubmission Date	HSC Approval Date Target	HSC Approval Date	Activation Date Target	Activation Date	Day
						2024-01-25
2023-06-18	2023-06-19		2023-06-02	2023-07-03	2023-06-21	
2023-10-05	2023-10-09		2023-12-20	2023-11-08	2024-02-13	

Showing 1 to 506 of 506 entries

Oldest Date Range

2023-01-01 to 2024-03-17

Primary Disease Working Group

No Filter

Principal Investigator (PI)

No Filter

Study Sponsor

No Filter

Stage

No Filter

Research Type

No Filter

Apply Filter

Data From: 2024-03-17

Days from DWG to Activation Days from DWG to ERC Days from ERC to Activation Days from ERC Ready to Activation Days from ERC Ready to PRMC Submission
 Days from DWG Submission to PRMC

Research Type	Mean	SD	Median	IQR	Count
Industrial/Pharmaceutical	139.54	34.31	137	59	13
National/Cooperative Group/Consortium	61.56	24.62	52	34.25	18
Total:	94.26	48.42	95	74	31

Oldest Date Range

2023-01-01 to 2024-03-17

Primary Disease Working Group

No Filter

Principal Investigator (PI)

No Filter

Study Sponsor

No Filter

Stage

No Filter

Research Type

No Filter

Apply Filter


Data From: 2024-03-17

Days from DWG to Activation

Days from DWG to ERC

Days from ERC to Activation

Days from ERC Ready to Activation



Oldest Date Range

to

Primary Disease Working Group

Principal Investigator (PI)


Study Sponsor

Stage

Research Type

Data From: 2024-03-24

Average(Days DWG To Activation) by Research Type



Study: XXXXXXXXXX

Drug Relatedness for these tables are pulled from free text fields entered by the study team.

Missing Attribution Adverse Events (No relatedness/non-relatedness listed for any drugs)

Related to Drugs (Drugs are considered related if given the status of Definitely Related, Possibly Related, Probably Related, or Related)

Romidepsin

Not Related to Drugs (Drugs are considered not related if given the status of Nevertaken, Not Related, Discontinued, or Unlikely)

No Filter

Severity

No Filter

Grade

No Filter

Start Date Range

to

Apply Filter

Relationship	Expected/Unexpected	Grade	Outcome	Serious Adverse Event				
Event	Expected	Not Assessed	Unexpected	Total				
Abdominal pain	2	0	0	2				
Acute kidney injury	1	0	0	1				
Alanine aminotransferase increased	0	2	0	2				
Alkaline phosphatase increased	3	3	2	8				
Anemia	50	2	0	52				
Anorexia	18	0	1	19				
Anxiety	1	0	0	1				
Arthralgia	6	0	0	6				
Aspartate aminotransferase increased	1	2	0	3				
Back pain	3	0	0	3				
Bloating	1	1	0	2				
Blood and lymphatic system disorders - Other, specify	0	0	1	1				
Blurred vision	2	0	0	2				
Bone pain	2	2	0	4				
Colitis	2	0	0	2				
Concentration impairment	0	1	0	1				
Constipation	18	3	0	21				

Study: [REDACTED]

All recorded deviations are shown below.

Category				
Deviation	Minor	Planned	Total	
Concomitant Therapy	2	0	2	
Eligibility Criteria	1	0	1	
Schedule of Event	43	3	46	
Site Pharmacy	1	0	1	
Study Therapy	5	0	5	
Total	52	3	55	

Related Automated Reports

- -Accrual Missing ZIP Code Report: Bi-Weekly
- -CATCHUP Report: Weekly
- -PRMC Email Notification: Daily
- -All Flows: Study Portfolio Flowchart Generator

Acknowledgments

- Matthew Mayo
- Byron Gajewski
- Dinesh Pal Mudaranthakam
- Natalie Streeter
- KUCC Clinical Trials Office
- Ron Chen
- Hope Krebill
- Karla
- OPTIK Team

Research reported in this publication was supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 and used BISR core

Thank you!

Sam Pepper

spepper@kumc.edu

